April 3rd, 2026
FDA Moves to Speed Biosimilar Development, Lower Prescription Drug Costs
The FDA has unveiled draft guidance to accelerate biosimilar approvals, reduce testing costs, and expand access to affordable biologic alternatives for cancer, autoimmune diseases, and other chronic conditions.